SpringWorks Therapeutics has entered into a clinical trial collaboration agreement with Precision Biosciences. Per the agreement, PBCAR269A, Precision BioSciences’ wholly-owned investigational allogeneic chimeric antigen receptor T cell therapy candidate targeting B-cell maturation antigen (BCMA) will be evaluated in combination with nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in patients with relapsed or refractory multiple myeloma … more
Separately, SpringWorks has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further explore the ability of nirogacestat to modulate BCMA and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models … more
Furthermore, SpringWorks has entered into a clinical collaboration and supply agreement with Janssen Biotech to evaluate nirogacestat in combination with Janssen’s bispecific antibody targeting BCMA and CD3, teclistamab, in patients with relapsed or refractory multiple myeloma … more
In addition, SpringWorks is collaborating with the Children’s Oncology Group to evaluate nirogacestat in a Phase 2 clinical trial for the treatment of children and adolescents with progressive, surgically unresectable desmoid tumors … more